News Focus
News Focus
Followers 4
Posts 323
Boards Moderated 0
Alias Born 07/27/2010

Re: jbog post# 16705

Thursday, 02/16/2017 8:06:51 PM

Thursday, February 16, 2017 8:06:51 PM

Post# of 20689
Would disagree with the Copaxone competition effect and pricing. Glatopa and/or others will be used as leverage by PBMs to move new starts away from the orals.

If you can purchase Glatopa for $25000 annually, they will move other MS drugs to Third tier or noncoverage status with prior auth required.